News

In December 2014, the company completed a Phase III actual use trial, which was intended to simulate the OTC use of Lipitor (atorvastatin calcium) 10mg. The program was

HM61713 is a new 3rd generation, orally active, irreversible EGFR mutation selective tyrosine kinase inhibitor (TKI). As part of the deal, Hanmi will receive an initial payment of

The deal will combine the institute’s clinical expertise and data with Biogen’s focus on neurodegenerative disease and approach to clinical development. Biogen chief scientific officer Spyros Artavanis-Tsakonas said:

As part of the deal, Sprint Bioscience licenses an early-stage inhibitor program targeting tumor metabolism to Bayer, which will later have full control over further development and worldwide

Caprelsa is indicated to treat symptomatic or progressive medullary thyroid carcinoma in patients with unresectable locally advanced or metastatic disease and is currently available in 28 countries. Currently,

The program is being funded by Global Health Innovative Technology Fund (GHIT), a public interest incorporated association and a fund for promoting the research and development of pharmaceuticals,

The companies entered into an exclusive license in July 2014 to discover, develop and commercialize these products for the treatment of sepsis. Yabao Pharmaceutical R&D president Dr Peng

HepTcell is a peptide-based immunotherapeutic which includes the company’s proprietary Densigen technology. The product candidate includes nine long peptides covering conserved regions of core, polymerase and surface proteins

The initiation of this human trial follows strong pre-clinical results revealing that INO-5150 generated healthy CD8+ T cell responses in animal studies including non-human primates. The company noted